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Abstract 
Transforming growth factor (TGF)-β contributes to the malignant phenotype of 
glioblastoma by promoting invasiveness and angiogenesis and creating an 
immunosuppressive microenvironment. So far, TGF-β1 and TGF-β2 isoforms have 
been considered to act in a similar fashion without isoform-specific function in 
glioblastoma. A pathogenic role for TGF-β3 in glioblastoma has not been defined yet. 
Here we studied the expression and functional role of endogenous and exogenous 
TGF-β3 in glioblastoma models. TGF-β3 mRNA is expressed in human and murine 
long-term glioma cell lines as well as in human glioma-initiating cell cultures with 
expression levels lower than TGF-β1 or TGF-β2 in most cell lines. Inhibition of TGF-
β3 mRNA expression by ISTH2020 or ISTH2023, two different isoform-specific 
phosphorothioate locked nucleic acid (LNA)-modified antisense oligonucleotide 
gapmers, blocks down-stream SMAD2 and SMAD1/5 phosphorylation in human LN-
308 cells, without affecting TGF-β1 or TGF-β2 mRNA expression or protein levels. 
Moreover, inhibition of TGF-β3 expression reduces invasiveness in vitro. 
Interestingly, depletion of TGF-β3 also attenuates signaling evoked by TGF-β1 or 
TGF-β2. In orthotopic syngeneic (SMA-560) and xenograft (LN-308) in vivo glioma 
models, expression of TGF-β3 as well of the down-stream target, plasminogen-
activator-inhibitor (PAI)-1, was reduced while TGF-β1 and TGF-β2 levels were 
unaffected following systemic treatment with TGF-β3-specific antisense 
oligonucleotides. 
We conclude that TGF-β3 might function as a gatekeeper controlling down-stream 
signaling despite high expression of TGF-β1 and TGF-β2 isoforms. Targeting TGF-β3 
in vivo may represent a promising strategy interfering with aberrant TGF-β signaling 
in glioblastoma.  
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Introduction 
 
Transforming growth factor (TGF)-β is a pleiotropic cytokine with multiple effects on 
cellular behavior including proliferation, migration, invasion, angiogenesis and 
immune responsiveness. The three TGF-β isoforms, TGF-β1, TGF-β2 and TGF-β3, 
exhibit high levels of similarity in their amino acid sequences, however, the tertiary 
structure of the active domain of TGF-β3 differs from TGF-β1 and TGF-β2, enabling 
steric rearrangements which allow a more flexible binding to TGF-β receptor II 
(TβRII) (1-5). TGF-β3 has an isoform-specific function in embryonic palate fusion and 
wound healing (6-8). The deficits of TGF-β3 knockout mice are almost exclusively 
restricted to impaired palate fusion and pulmonary abnormalities (9). In contrast, mice 
with a gene knockout for TGF-β1 or TGF-β2 exhibit multi-organ deficits, TGF-β1 
especially in the hematopoietic and vasculogenic system and TGF-β2 in multiple 
embryonal developmental processes including the development of heart, lung, 
neurons and bones (10, 11). The different phenotypes of TGF-β isoform knockout 
mice point towards non-overlapping isotype-specific functions. Reports on TGF-β3 in 
cancer are almost exclusively restricted to expression analyses and correlative 
studies without revealing an isotype-specific functional role (5).  
Aberrant TGF-β signaling is considered as a hallmark for the malignant phenotype of 
glioblastoma. All the three TGF-β isoforms, TGF-β1, TGF-β2 and TGF-β3 are 
expressed in malignant gliomas in vivo (12, 13). However, pathogenic effects in 
glioblastoma have been only attributed to the isoforms TGF-β1 and TGF-β2 while 
there are no functional data for TGF-β3 (14-16). 
Molecular subtyping has identified TGF-β3 as a gene highly expressed in the 
classical glioblastoma subtype (17). Still, the functional role of TGF-β3 in the 
malignant phenotype of glioblastoma remains uncertain, and its mRNA expression 
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levels in vivo are lower than those of TGF-β1 and TGF-β2 (13). Here, we characterize 
the expression and biological activity of TGF-β3 using isoform-specific 
oligonucleotides in human and murine glioma models.   
 
Materials and methods 
Cell culture 
Nine human long-term malignant glioma cell lines (LTC), obtained in 1994, were 
previously described (18) and sent for authentification tests to the German Biological 
Resource Centre DSMZ in Braunschweig, Germany, in November 2013. The 
spontaneous murine astrocytoma (SMA) cell lines (SMA-497, SMA-540, and SMA-
560) kindly provided by Dr D. Bigner (Durham, NC) were previously characterized 
(19-21).  Murine GL-261 cells were obtained from the National Cancer Institute 
(Frederick, MD). Five human glioma-initiating cell (GIC) lines, established after 
informed consent and approval of the local ethics committees have been previously 
described (22-24). 
 
Reagents 
Human and murine LTC were cultured in Dulbecco´s modified Eagle´s medium 
supplemented with 10% fetal calf serum. GIC were maintained in Neurobasal 
Medium supplemented with B-27 (20 μl/ml) and glutamine (10 μl/ml) from Invitrogen 
(Basel, Switzerland), fibroblast growth factor-2 and epidermal growth factor (20 ng/ml 
each; Peprotech, Rocky Hill, PA). Recombinant TGF-β1, TGF-β2, and TGF-β3 (R&D, 
Minneapolis, MN) were used as indicated. TGF-β3-targeted oligonucleotides 
ISTH2020, ISTH2023 and control oligonucleotide C3_ISTH0047 were designed and 
provided by Isarna Therapeutics (Munich, Germany). ISTH2020 (sequence 
TTTGTTTACACTTCC) and ISTH2023 (sequence GAGTTTTTCCTTAGG) represent 
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fully phosphorothioate locked nucleic acid (LNA)-modified antisense oligonucleotides 
(Supplementary Figure 1). For overexpression of TGF-β3, a plasmid containing an 
untagged human cDNA clone of TGF-β3 (NM_003239) transfected in a pCMV6-XL5 
vector was used (SC118071, Origene, Rockville, MD). Lipofection-based 
transfections were done with Lipofectamine RNAimax and Opti-MEM (Invitrogen). 
 
Transfections 
For lipofection-aided transfections, LTC were transfected at subconfluent conditions 
in serum-containing medium at a density of 75 000 cells/cm2 by adding a transfection 
mix of transfection reagent and oligonucleotides prepared in Opti-MEM medium. After 
12-24 h cells were washed and exposed to serum-free medium for 24-120 h as 
indicated.  
For gymnotic transfections, no transfection reagent was used. LTC were seeded at 
low densities (13 000 cells/cm2) and treated after 6-12 h with the indicated 
concentrations of oligonucleotide in full serum-containing medium. On the 3rd day 
after seeding, full medium supplemented with oligonucleotide was renewed. On the 
7th day, medium was removed and the cells were exposed to serum-free-medium. 
 
Trypan blue exclusion assay 
Cells were seeded and transfected as described. To obtain counts for dead and 
viable cells, cell culture supernatant was removed, cells were detached and counted 
including the cells of the supernatant in an automatic trypan blue-based cell counter 
(Vi-Cell, Beckman Coulter Inc, Brea, CA) in 3 or 4 replicates. 
 
Immunoblot  
Targeting TGF-β3 in glioblastoma 
7 
 
Supernatants were generated in serum-free medium after the indicated time points 
and centrifuged to remove cellular debris. Supernatants were concentrated using a 
centrifugal filter device (3 kD cut-off, Millipore, Eschborn, Germany). Whole cell lysate 
preparation and quantification of protein levels were performed as previously 
described (23). After SDS-PAGE under reducing conditions, proteins were 
transferred to nitrocellulose membranes (Biorad, Munich, Germany) and blocked in 
Tris-buffered saline containing 5% skim milk and 0.1% Tween 20 following antibody 
incubation (antibody information see supplementary methods).  
Visualization of protein bands was performed with horseradish peroxidase (HRP)-
coupled secondary antibodies (Santa Cruz Biotechnology) and enhanced 
chemoluminescence (Pierce/Thermo Fisher, Madison, WI). Quantification of bands 
for correlation analyses was done using ImageJ software (Open Source). 
 
Real-time PCR  
mRNA extraction was done using the NucleoSpin® RNA II system (Macherey-Nagel, 
Düren, Germany) including DNase treatment. cDNA was prepared using a cDNA 
reverse transcription kit (Applied Biosystems, Forster City, CA). 
Gene expression was determined via real-time PCR (23) using ADP-ribosylation 
factor 1 (ARF-1) as a housekeeping gene with the ΔCTT-method for relative 
quantification. Primer sequences are indicated in the supplementary material section. 
 
Invasion 
For invasion assays, glioma spheroids were generated by incubating 1,500 cells for 
72 h in full medium in 96-well plates precoated with 1% Noble Agar (Becton 
Dickinson, Franklin Lakes, NJ). Thereafter, spheroids were embedded into a collagen 
matrix containing collagen type I (Corning, NY) in full medium at neutral pH in a 96-
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well plate. Sprouting of spheroids was monitored by photographs. For quantification, 
the median invaded distance of 30 cells was assessed using ImageJ software. The 
spheroid margin at the corresponding time point was used as a reference for 
measurement of the invaded distance of sprouting cells.  
 
Animal studies and histology 
In vivo studies were performed as previously described (25). In brief, VM/Dk mice 
(Charles River, Sulzfeld, Germany) were stereotactically implanted into the right 
striatum with 5 x 103 SMA glioma cells, C57Bl/6 mice with 2 x 104 GL-261 cells and 
immunodeficient Crl:CD1-Foxn1nu nude mice (Charles River) with 105 cells human 
LN-308 glioma cells in a volume of 2 µl of phosphate-buffered saline (Gibco, Life 
Technologies). Animal studies were approved by Cantonal Veterinary Office Zurich 
and Federal Food Safety and Veterinary Office (Permission number 202/2012). For 
ex vivo expression analyses without systemic treatment, the tumor or the non-tumor 
bearing left hemisphere, considered as “normal brain”, were subjected to mRNA 
extraction on day 12 after implantation.  
Systemic treatment with oligonucleotides was performed by subcutaneous injections 
as indicated. Brains were collected upon euthanization, embedded in cryomoulds in 
Shandon Cytochrome yellow (Thermo Scientific, Waltham, MA) and frozen. For 
histology, brains were cut in 8 μm sections using a Microm HM560 (Microchom 
HM560, Thermo Scientific) and every 20th section was stained with hematoxylin and 
eosin (H&E) (25). Tumor volumes were determined using an approximation based on 
ellipsoid geometric primitive (26). For analysis of invasiveness in vivo, we counted 
satellite lesions as defined by tumor cell aggregates >10 cells at least 3 cell layers 
distant from the main tumor bulk on all H&E-stained sections.  
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Database interrogations 
The Cancer Genome Atlas (TCGA) database and the R2 microarray analysis and 
visualization platform (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi#, available on 26th 
of February) were used to perform survival analyses within the glioblastoma data set 
containing gene expression data.  
 
Statistical analysis 
Representative experiments, commonly performed three times with similar results, 
are shown. Statistical calculations were done using the software of GraphPad Prism 
Version 5 (San Diego, CA) including two-sided unpaired t-test (comparison of two 
groups), one-way ANOVA and Bonferroni post-hoc testing (multiple comparisons) 
and Spearman correlation coefficient for correlation analyses. A p-value of 0.05 was 
considered statistically significant.  
 
Results 
High TGF-β3 expression is associated with poor survival in glioblastoma 
To assess whether TGF-β3 expression correlates with survival, we used the 
database of the Cancer Genome Atlas (TCGA) containing data on mRNA expression 
levels and clinical course of more than 500 patients with glioblastoma. High TGF-β3 
expression was associated with poor survival (13). We next asked whether this 
association varies within the molecular subtypes classified by Verhaak and 
colleagues (17). Stratifying patients into these subgroups, data of 82 patients with 
tumors of the neural, 88 of the proneural, 146 of the mesenchymal and 142 of the 
classic subtype were available (Supplementary Figure 2). Notably, in the group of the 
neural subtype the survival benefit for patients with lower TGF-β3 mRNA expression 
was highly significant. This was true both when segregating groups into high and low 
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expression using the cut-off resulting in the highest association (p=0.01, 
Supplementary Figure 2A) and when using the median expression level as cut-off 
(p=0.003) (Supplementary Figure 2B). 
 
TGF-β3 is expressed on mRNA and protein level in glioma cell lines 
We next characterized our panel of 14 human glioma cell lines (9 LTC, 5 GIC) and 4 
murine glioma cell lines for TGF-β3 expression. TGF-β3 mRNA was expressed in all 
human cell lines without apparent differences between LTC and GIC (Figure 1A). 
TGF-β3 mRNA expression levels were much lower than those of TGF-β1 or TGF-β2 in 
8 of 9 LTC whereas GIC did not show this pattern (Supplementary Figure 3A, data on 
human TGF-β1,2 mRNA been published previously (23)). Murine cell lines expressed 
TGF-β3 mRNA, too (Figure 1B). For the murine cell lines, we further assessed the 
expression levels ex vivo, i.e. we implanted the cells orthotopically in syngeneic mice 
and extracted mRNA from the non-tumor-bearing left hemisphere considered as 
normal brain and from the tumor after removal from the right hemisphere. Mean 
levels of TGF-β3 mRNA in tumoral ex vivo samples were more than 3-fold higher in 
SMA-540 and SMA-560, comparable in GL-261 and more than 5-fold lower in SMA-
497 compared to normal brain (Figure 1C). SMA-497 showed the highest mRNA 
expression in vitro, but the lowest ex vivo. Comparing all TGF-β isoforms in vitro, 
TGF-β1 was the predominant isoform in SMA-540 and SMA-560, while no significant 
difference between the isoforms was detected in SMA-497 and GL-261. Ex vivo, both 
TGF-β1 and TGF-β3 were preferentially expressed in SMA-560, TGF-β3 was higher 
than TGF-β2 in SMA-540 while in line with the expression profile in vitro, SMA-497 
and GL-261 did not show significant differences between the isoforms 
(Supplementary Figure 3 B,C, data on murine TGF-β1,2 mRNA expression have been 
published previously (27)). 
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We next analyzed TGF-β3 protein levels in whole cell lysates and cell culture 
supernatants which turned out to be challenging. The best antibody we identified 
(ab15537) still had some cross-reactivity with TGF-β2 as assessed by immunoblot 
loaded with recombinant TGF-β1/2 (Supplementary Figure 4). Still, we considered the 
detected protein bands as a valid signal since treatment with TGF-β3-specific 
oligonucleotides reduced the bands at 50 kDa and 12.5 kDa, the presumable pro-
form and active form of TGF-β3. Further, these bands increased upon 
overexpression of TGF-β3 (Figure 1D). In whole cell lysates, the pro-form of TGF-β3, 
but not the active form, was detected in all cell lines, with the highest levels in T98G, 
U87MG and LN-308 among LTC, and in T-325 among GIC (Figure 1E). In cell culture 
supernatants, the pro-form and the active forms of TGF-β3 were detected, with 
highest levels in LN-428 and T98G, and lower levels in GIC (Figure 1F). TGF-β3 
mRNA levels neither correlated with TGF-β3 protein in whole cell lysates nor in the 
supernatant. However, in the cell culture supernatants, TGF-β3 proform levels 
correlated with its active form (r=0.64, p=0.01). 
In whole cell lysates of mouse glioma cells, the levels of the pro-form of TGF-β3 were 
similar while levels of the active form were again not detected (Figure 1G). In cell 
culture supernatants, SMA-497 showed the highest levels of TGF-β3 (pro- and active 
form) with low levels of active TGF-β3 in the other cell lines (Figure 1H). 
 
Stimulation with different TGF-β isoforms does not disclose isoform-specific effects 
for pSMAD2 
We next confirmed the responsiveness to exogenous TGF-β with regard to isotype-
specific functions at the level of canonical signalling. LN-18, U87MG, T98G, LN-308 
or LN-229 cells were exposed to increasing concentrations of TGF-β1/2/3. All cell lines 
Targeting TGF-β3 in glioblastoma 
12 
 
showed a concentration-dependent induction of pSMAD2 by all TGF-β isoforms 
(Figure 1I). No isoform-specific effect was identified. 
 
TGF-β3-targeted oligonucleotides specifically down-regulate TGF-β3 mRNA in a time- 
and concentration-dependent manner 
We next analysed the activity and specificity of TGF-β3-targeted oligonucleotides 
(ISTH2020 and ISTH2023) in the human LTC LN-308 characterized by high 
endogenous TGF-β1 and TGF-β2 levels and high constitutive pSMAD2 and 
pSMAD1/5 phosphorylation (23, 28). We applied lipofection-based transfections in a 
nanomolar range and gymnotic transfection without transfection reagent in a 
micromolar range. Both oligonucleotides down-regulated TGF-β3 mRNA in a time- 
and concentration-dependent manner (Figure 2). Both at 24 h and at 72 h, TGF-β3 
mRNA was reduced by more than 75% at 25 nM of ISTH2020 or ISTH2023 using 
lipofection-based transfection. Of note, in this model, mRNA levels of TGF-β1 and 
TGF-β2 are more than 100-fold higher than those of TGF-β3. TGF-β1 and TGF-β2 
were not reduced by more than 50% upon treatment with TGF-β3-targeted 
oligonucleotides (Figure 2A). With the gymnotic transfection method, mimicking the 
systemic administration of the oligonucleotides in vivo, ISTH2020 or ISTH2023 at 5 
µM led to more than 95% reduction of TGF-β3 mRNA at day 6 and more than 80% 
reduction at day 8 of treatment, without affecting TGF-β1 or TGF-β2 mRNA by more 
than 2-fold (Figure 2B). The effect of the oligonucleotides on TGF-β3 was 
concentration-dependent with a reduction of more than 50% of TGF-β3 mRNA up to 
12.5 nM (ISTH2020) and 25 nM (ISTH2023) (Figure 2C) with lipofection and up to 0.6 
µM (ISTH2023) with gymnotic treatment (Figure 2D). ISTH2020 and ISTH2023 
showed comparable activity in the mouse glioma cell line SMA-560 with up to 60% 
reduction of TGF-β3 mRNA at 20 nM at 24 and 96 h after lipofection-aided 
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transfection (Figure 2E) and up to 90% reduction of TGF-β3 mRNA with gymnotic 
transfection at 5 µM on day 6 (Figure 2F). With lipofection-based transfection at 50 
nM, there was no effect on cell viability or proliferation between 24 and 96 h after 
transfection (Supplementary Figure 5A). Similarly, with the gymnotic transfection 
method at 2.5 µM, there were neither significant effects on cell viability nor 
proliferation between day 4 and 8 of treatment (Supplementary Figure 5B).  
 
Inhibition of TGF-β3 via oligonucleotides reduces SMAD2 and pSMAD1/5 
phosphorylation without affecting TGF-β1 and TGF-β2 levels 
We next asked whether treatment with TGF-β3-targeted oligonucleotides affects 
down-stream signaling. With lipofection, pSMAD2 and pSMAD1/5 levels were time- 
and concentration-dependently down-regulated by both oligonucleotides (Figure 
3A,B). Gymnotic delivery of 2.5 µM ISTH2020 or ISTH2023 reduced pSMAD2 
earliest on day 7 with the most pronounced effect on day 8. SMAD1/5 
phosphorylation was reduced on day 8 (Figure 3C). The effect on SMAD2 and 
SMAD1/5 phosphorylation was also concentration-dependent as assessed with 
ISTH2023, however, lower concentrations than 2.5 µM had no effect on SMAD 
phosphorylation (Figure 3D). Of note, TGF-β1 and TGF-β2 protein levels in the cell 
culture supernatant were unaffected after 120 h exposure of oligonucleotides (25 nM) 
with lipofection-aided transfection (Supplementary Figure 6A) and on day 8 of 
gymnotic treatment with 2.5 µM (Supplementary Figure 6B). We next extended our 
analysis to the human LTC T98G, and the murine cell line SMA-560. In T98G and 
SMA-560 cells, both TGF-β3-targeted oligonucleotides reduced SMAD2 
phosphorylation, too (Figure 3E).  
 
TGF-β3 gene silencing reduces invasiveness in vitro 
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TGF-β isoforms are involved in regulating tumor cell invasiveness (29) and TGF-β3 
has been attributed isoform-specific effects in wound healing (8), a process involving 
cell migration and invasion. We therefore assessed whether inhibition of TGF-β3 
affected invasiveness of LN-308 glioma cells. Invasiveness was reduced by silencing 
of TGF-β3 with either ISTH2020 or ISTH2023 (Figure 4).  
 
TGF-β3-targeted oligonucleotides inhibit SMAD phosphorylation induced by 
exogenous TGF-β1/2/3 
We next asked whether the inhibitory effect on SMAD phosphorylation by TGF-β3-
targeted oligonucleotides is preserved upon additional stimulation with other TGF-β 
isoforms. Surprisingly, SMAD2 and SMAD1/5 phosphorylation were induced less by 
TGF-β1/2 at 0.5 ng/ml in the presence of TGF-β3-targeted oligonucleotides. This 
effect still held true for SMAD2 phosphorylation at higher concentrations (5 ng/ml) of 
TGF-β1 and TGF-β2 (Figure 5). 
 
Inhibition of TGF-β3 in vivo  
The TGF-β3-targeted oligonucleotides ISTH2020 and ISTH2023 were shown to 
exhibit no liver toxicity upon systemic administration as assessed by plasma alanin-
transaminase (ALT) in murine models (M. Janicot, unpublished observation). To 
verify target inhibition in vivo, we systemically treated mice bearing syngeneic (SMA-
560) or xenograft (LN-308) gliomas with control or ISTH2023 oligonucleotides. 
Tumors derived from SMA-560 cells showed significantly higher mRNA expression of 
TGF-β3 than normal brain. Upon treatment with ISTH2023, tumoral mRNA levels of 
TGF-β3 were reduced by more than 30% (Figure 6A). Importantly, PAI-1 as a 
transcriptional down-stream target was significantly reduced in ISTH2023-treated 
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tumors (Figure 6B). Similar to the in vitro data, levels of TGF-β1/2 were not altered by 
ISTH2023 (Figure 6C).  
In the xenograft LN-308 model, ISTH2023 significantly reduced human TGF-β3 
(Figure 6D) and human PAI-1 (Figure 6E) mRNA levels while tumoral human TGF-
β1/2 was not affected significantly (Figure 6F). 
We next asked whether treatment with TGF-β3-targeted oligonucleotides affects the 
phenotype of experimental gliomas in vivo. Tumor size as assessed by volumetric 
measurement of H&E-stained slides was not significantly affected by ISTH2023 
either in the SMA-560 (Figure 6G) or in the LN-308 model (Figure 6J). However, a 
trend towards a reduced tumor size was observed in both models in mice treated with 
ISTH2023. In the SMA-560 model, we assessed the number of satellite lesions as a 
morphologic surrogate marker of tumor invasiveness. The mean number of satellite 
lesions per brain section was 5 in the control group versus 3 in the group treated with 
ISTH2023. This reduction was not significant (p=0.41) when comparing the mean 
number of satellites per section of the 4 brains per group, but was significant 
(p=0.0036) when comparing the results of all H&E-stained brain sections per group 
(n=149 “control” versus n=148 “ISTH2023”) (Figure 6H, representative images shown 
in Figure 6I). In the LN-308 model, assessment of satellite lesions was not 
meaningful since the mean number of satellites per brain section was less than 1 in 
either group (representative images shown in Figure 6K).  
 
Discussion 
The TGF-β pathway has been attributed a key role in the pathogenesis of 
glioblastoma with regard to immunosuppression, invasion, angiogenesis and 
maintenance of the stem cell phenotype (30, 31). Pharmacological strategies to 
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interfere with the TGF-β pathway via inhibition of the kinase activity of TGF-β-
receptor type I were promising in murine models, but so far disappointing in the clinic 
(29, 32-34). A ligand-based approach using AP-12009, an antisense oligonucleotide 
supposed to target TGF-β2, administered intratumorally, suggested non-inferiority to 
alkylating chemotherapy in a phase II clinical trial, however, interpretation of the trial 
results remained controversial (35, 36).  
Targeting the ligands rather than their bona fide receptors might have different 
therapeutic safety, tolerability and efficacy profiles. Beyond AP-12009, a TGF-β2-
antisense-modified tumor cell vaccine as another ligand-based approach of targeting 
the TGF-β pathway in glioblastoma has been tested in the clinic in a phase I trial 
(37). Targeting TGF-β expression through integrin inhibition has yielded promising 
results in vitro (38) but was not active in glioblastoma patients (39). TGF-β1 and TGF-
β2 were considered as the most important isoforms in glioblastoma while little is 
known on the role of TGF-β3 in the context of glioblastoma (13). 
Here, we present a comprehensive analysis of TGF-β3 mRNA and protein expression 
in human and murine in vitro models and show that TGF-β3 expression can be 
specifically inhibited by oligonucleotides in vitro and in vivo.  This inhibition led to 
down-regulation of SMAD signaling in vitro and of the SMAD-dependent target gene 
PAI-1 in vivo despite the presence of TGF-β1 and TGF-β2. 
The fact that high TGF-β3 mRNA expression correlates with poor survival in 
glioblastoma patients in the TCGA database (13) suggests targeting of TGF-β3 as a 
promising strategy. A previous study performed using the Rembrandt database 
showed that expression levels of more than 2-fold of TGF-β1 (p=0.02) or more than 
5-fold of TGF-β2 (p=0.05) correlated with poor survival while more than 2-fold 
expression of TGF-β3 was without prognostic significance (p=0.08) (16). Divergent 
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results regarding a prognostic role of TGF-β3 expression might be due to different 
samples in the respective databases with tumors exhibiting genetic heterogeneity or 
the use of different cut-offs. This would be in line with our observation that the 
association of TGF-β3 mRNA expression with poor survival is most prominent in the 
neural subtype of the Verhaak classification (Supplementary Figure 2). These data 
suggest that therapeutic targeting of TGF-β3 might be most effective in these tumors.  
We show that TGF-β3 expression in human glioma cell lines is less abundant than 
that of TGF-β1 and TGF-β2, in line with a previous study based on glioblastoma 
tissue samples (13), however, GIC did not show this pattern (Supplementary Figure 
3A). Intracellular protein levels of TGF-β3 were detected in all human and murine cell 
lines while the 12.5 kDa secreted form of TGF-β3 was present in the majority of 
human LTC, but not GIC (Figure 1D-F). This might reflect a different importance of 
this isoform in these cell types. All three TGF-β isoforms induced SMAD2 
phosphorylation in a concentration-dependent manner (Figure 1I), not revealing 
isoform-specific differences. However, specific time- and concentration-dependent 
inhibition of endogenous TGF-β3 by oligonucleotides (Figure 2) reduced SMAD2 and 
SMAD1/5 phosphorylation despite the concurrent presence of TGF-β1/2 which would 
be expected to be major and sufficient drivers of baseline phosphorylation levels 
(Figure 3). The gymnotic transfection method with omission of transfection reagent 
and micromolar concentrations intends to mimic the systemic administration of the 
drug in vivo and led to a similarly effective inhibition of TGF-β3 expression and 
reduction of SMAD2 and SMAD1/5 phosphorylation as the conventional lipofection-
based transfection method (Figures 2,3). 
The profound effect of inhibition of TGF-β3 on SMAD phosphorylation, albeit 
expressed at mRNA levels much lower than those of TGF-β1/2 in these cells, 
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suggests a major distinct regulatory role of this isoform. The reduction in 
phosphorylated SMAD levels by inhibition of TGF-β3 leading to reduced invasiveness 
in the LN-308 model (Figure 4) points towards biological and clinical relevance of 
targeting TGF-β3 in glioblastoma. 
The hypothesis that TGF-β3 might exert major biological effects despite its low 
expression levels and concurrent presence of the other TGF-β isoforms is further 
supported by our observation that TGF-β3-specific oligonucleotides reduce SMAD 
phosphorylation even in the presence of exogenous TGF-β1/2 (Figure 5). For the 
three TGF-β isoforms, auto-feedback loops inducing their own expression mediated 
by different transcription factors according to the respective isoform with differential 
promotor regions have been suggested (16, 40, 41). An impaired auto-feedback loop 
through resulting from TGF-β3 depletion might explain the profound effects on SMAD 
phosphorylation despite the presence of the other isoforms. TGF-β3-dependent 
epithelial-mesenchymal transition is downstream of a TGF-β1- and TGF-β2-induced 
upregulation of the E-cadherin repressors snail and slug (42), supporting the concept 
of hierarchical importance of the different isoforms. Potentially, TGF-β3 functions as a 
gatekeeper controlling down-stream signaling despite high expression of TGF-β1 and 
TGF-β2 isoforms. 
Treatment with the TGF-β3-specific oligonucleotides in vivo also resulted in specific 
target down-regulation without significant effects on the other TGF-β isoforms. 
Biological relevance of reduced TGF-β3 levels was demonstrated by profound down-
regulation of the SMAD-dependent target gene PAI-1 both in the syngeneic SMA-560 
and xenograft LN-308 model (Figure 6). Short-term inhibition of TGF-β3 in vivo 
showed only a minor, non-significant reduction of tumor volumes (Figure 6), in line 
with the observation that there are no significant effects on cell viability nor 
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proliferation in vitro (Supplementary Figure 5). Reduced TGF-β3 levels were 
associated with a minor reduction of tumor invasiveness in vivo (Figure 6), but 
prolonged exposure to inhibitors is probably necessary for more prominent effects. 
Further, inhibition of TGF-β3 alone might not be sufficient to block tumor 
invasiveness, given the complexity in vivo involving other drivers of tumor invasion 
and potential escape mechanisms. 
In summary, we demonstrate that isoform-specific targeting of TGF-β3 is feasible and 
effective by subcutaneous injection of a suitable oligonucleotide. 
Pharmacological inhibition of TGF-β3 in glioblastoma may therefore represent a 
promising strategy warranting further investigation.  
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Figure Legends 
 
Figure 1. TGF-β3 mRNA expression and TGF-β3 protein levels in glioma cell 
lines.  
A-C. The expression of TGF-β3 mRNA in human (A) and murine cell lines in vitro (B) 
and ex vivo (C) was assessed by RT-PCR. As a control for ex vivo samples, 
expression levels of normal syngeneic mouse brain (NB) were included. Results are 
expressed as means and SD (n=3 independent samples, except D-247MG with n=1; 
n=1 for NB). D-H. TGF-β3 protein levels were assessed by immunoblot. The 
specificity of the bands was verified by lipofection-based transfection with TGF-β3-
targeted antisense oligonucleotides in whole cell lysates of human LN-308 and 
murine SMA-560 cells (control versus ISTH2020 or ISTH2023 at 50 nM collected at 
96 h after transfection for LN-308 and at 25 nM collected 72 h after transfection for 
SMA-560) and in supernatants of LN-308 cells (collected 96 h after transfection with 
control, ISTH2020 or ISTH2023 at 50 nM) and in supernatants of LN-18 cells (empty 
vector versus genetic overexpression of TGF-β3) (D). TGF-β3 protein levels were 
examined in cell lysates (E, G) and cell culture supernatants (F, H) of human (E, F) 
and murine cell lines (G,H) by immunoblot and quantification of bands by 
densitometric analyses using ImageJ. I. LN-18, U87MG, T98G, LN-308 or LN-229 
cells were stimulated with TGF-β1/2/3 at 0.1, 1 or 10 ng for 24 h. Whole cell lysates 
were analysed for pSMAD2. Actin, GAPDH (cell lysates) or Ponceau (supernatants) 
served as loading controls. 
 
Figure 2. Specific down-regulation of TGF-β3 mRNA by oligonucleotides.  
A-D. TGF-β1,2,3 mRNA expression was analysed by RT-PCR in LN-308 cells after 
treatment with control or TGF-β3-targeted oligonucleotides ISTH2020 or ISTH2023 
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via lipofection at 25 nM after 24 h or 72 h (A) or via gymnotic transfection after 6 and 
8 days at 5 µM (B), at 12.5, 25 or 50 nM after 24 h via lipofection (C) and at 0.3, 0.6, 
1.3, 2.5 or 5 µM after 8 days (D). Data shown in C and D were normalized to 
corresponding control. E,F. SMA-560 cells were analyzed for TGF-β3 mRNA 
expression after transfection with control or TGF-β3-targeted oligonucleotides via 
lipofection (E, 24 h or 96 h at 5 or 20 nM) or gymnotic transfection (F, 5 µM, day 6). 
Results shown in A-E are expressed as means of representative experiments 
performed in duplicates. 
 
Figure 3. TGF-β3 gene silencing interferes with down-stream SMAD signaling  
A-D. LN-308 cells were transfected with control or ISTH2020 and ISTH2023 via 
lipofection at 25 nM for 48 h or 120 h (A), at 25, 50 and 100 nM (B) or via gymnotic 
transfection for 7 and 8 days at 2.5 µM (C), and at 1.3, 2.5 and 5 µM for 8 days (D). 
pSMAD2, pSMAD1/5, TGF-β3 and actin/GAPDH as loading controls were analysed 
in whole cell lysates and TGF-β3 in cell culture supernatants (SN) by immunoblot.  
E. Whole cell lysates of T98G cells harvested 96 h after lipofection with 50 nM of 
control or TGF-β3-targeted oligonucleotide were analyzed for pSMAD2. SMA-560 
cells were treated similarly with 25 nM oligonucleotide, lysates harvested 72h after 
transfection, and analyzed for pSMAD2. Actin was included as a loading control. 
 
Figure 4. Silencing of TGF-β3 reduces invasiveness in vitro.  
A. Spheroids of LN-308 cells were generated by incubating 1,500 cells for 72 h in 
plates precoated with 1% agar, plated in a 3D collagen I matrix and evaluated at 
baseline (0 h) and after 48, 72 and 96 h (representative images). During spheroid 
generation and the invasion assay, the cells were exposed to control (left) or 
oligonucleotide treatment with ISTH2020 (middle) or ISTH2023 (right, gymnotic 
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delivery, 2.5 μM). B. The invaded area was analysed after the indicated time points 
(means and SD of a representative experiment performed in n=3 replicates (control, 
ISTH2023) or n=4 replicates (ISTH2020), one-way-ANOVA and Bonferroni post-hoc 
tests).   
 
Figure 5. TGF-β3-targeted oligonucleotides inhibit SMAD phosphorylation 
induced by TGF-β1/2 isoforms. LN-308 cells were transfected with control, 
ISTH2020 or ISTH2023 oligonucleotides (lipofection, 50 nM) and were stimulated 48 
h after transfection with or without TGF-β1/2 at 0.5 ng/ml and 5 ng/ml for 1 h. Whole 
cell lysates were analysed for pSMAD2, pSMAD1/5 and actin as a loading control.   
 
Figure 6. Inhibition of TGF-β3 by isoform-specific oligonucleotides in vivo.  
A-C. VM/Dk mice, orthotopically implanted with SMA-560 cells, were subcutaneously 
treated with control or ISTH2023 oligonucleotides at 20 mg/kg body weight for 5 
consecutive days, starting on day 5 after implantation. Brains were removed 24 h 
after the last treatment. Murine TGF-β3 (A), PAI-1 (B) or TGF-β1/2 mRNA (C) levels 
were assessed by RT-PCR in left hemisphere considered as normal brain (NB) and 
the tumor-bearing right hemisphere (Tu). Results are expressed as means and SD of 
n=4 mice per group. D-F. Nude mice, orthotopically implanted with LN-308 cells, 
were treated as in A-C, but starting on day 30 after implantation for 5 consecutive 
days. Human TGF-β3 (D), PAI-1 (E), or TGF-β1/2 (F) mRNA levels were assessed as 
in A-C. G-I. VM/Dk mice, orthotopically implanted with SMA-560 cells, were treated 
as in A-C followed by 3 injections per week until the first mouse in the experiment 
developed neurological symptoms. On H&E stained brain sections, tumor volume (G, 
means and SD of n=4 mice per group) and tumor satellites (H, means and SD of the 
mean number of satellites per section of n=4 tumors per group (upper panel) and 
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means and SD of all stained sections (n=149 control versus n=148 ISTH2023, lower 
panel)) were assessed as described in the methods section; I shows representative 
images (scale bars correspond to 100 µm). J-K. Nude mice, orthotopically implanted 
with LN-308 cells, were treated with control or ISTH2023, starting the treatment on 
day 21 with 5 daily injections followed by 3 injections per week until the first mouse 
became symptomatic. Tumor volume (J) was assessed as in G and representative 
images are shown in K (scale bars 100 µm). A-J. Statistics were performed with one-
way ANOVA and Bonferroni post-hoc testing in case of multiple comparisons (A-C, F) 
or t-test (D, E, G, H, J). 






Supplementary Figure 1. Structure of ISTH2020 and ISTH2023 
A-B. Schematic of the synthetic 15-mer antisense phosphorothioate oligonucleotides 
ISTH2020 (A) and ISTH2023 (B) sodium salt modified with locked nucleic acid (LNA) 
nucleosides (‘3+3’ LNA-modified gapmer) 
 
Supplementary Figure 2. TGF-β3 expression and patient survival, stratified for 
Verhaak subtypes – an analysis of the TCGA database.  
Kaplan-Meier estimation for overall survival probability of patients with high (blue 
curve) versus low (red curve) TGF-β3 mRNA expression derived of the TCGA 
database with data of > 500 glioblastoma patients stratified in the four different 
Verhaak subtypes, i.e. the neural, proneural, mesenchymal and classic subtype. The 
cut-off to segregate patients into groups of high and low expression was defined by 
the expression level that results in the highest association with survival (A) or by the 
median expression level of the target (B). Statistical significance (p) as assessed by 
log-rank test is indicated. 
 
Supplementary Figure 3. Expression of TGF-β1,2,3 in human and murine glioma 
cell lines. 
Human glioma LTC and GIC (A) and murine LTC (means and SD) in vitro (B) and ex 
vivo (C) were analyzed for expression of TGF-β1,2,3 by RT-PCR. As a control for ex 
vivo samples, normal syngeneic mouse brain (NB) was included. Results are 
expressed as means of duplicates (A) or means and SD of for n=3 independent cell 
line samples and n=1 for NB (B, C). Statistical significance was assessed by one-way 
ANOVA and Bonferroni post-hoc testing (B, C).  
 
Supplementary Figure 4: Validation of TGF-β antibodies.  
Immunoblot loaded with human recombinant TGF-β1,2,3 and analysed using 
antibodies to TGF-β1 (G1221), TGF-β2 (ab36495) or TGF-β3 (ab15537). 
 
Supplementary Figure 5: TGF-β3-targeted oligonucleotides: effects on viability 
and proliferation. A. Viable or dead LN-308 cells were quantified by trypan blue-
based automatic cell counting at 24, 48, 72 or 96 h after lipofection-aided transfection 
with oligonucleotides at 50 nM. Shown are means and SD of triplicates of a 
representative experiment. Viable or dead cells after transfection with control 
oligonucleotides were compared with the treatment with ISTH2020 and ISTH2023 
oligonucleotides using one-way ANOVA and Bonferroni post-hoc testing showing no 
significant differences (p>0.05). B. LN-308 cells were treated with 2.5 µM of 
oligonucleotides for 4 to 8 days. Viable or dead cells were assessed as in A. Shown 
are means and SD of 4 replicates of a representative experiment. 
 
Supplementary Figure 6. TGF-β3 gene silencing does not affect TGF-β1 and 
TGF-β2 protein levels.  
A-B. Cell culture supernatant of LN-308 cells was analysed for TGF-β1 and TGF-β2 
after treatment with control or TGF-β3-targeted oligonucleotide via lipofection (25 nM, 
120 h after transfection, A) or gymnotic transfection (2.5 µM, day 8, B).  
 
 






Supplementary material 
Real time PCR 
The following primer sequences were used: human ARF-1 (forward 5'-TCC CAC 
ACA GTG AAG CTG ATG-3', reverse 5'-GAC CAC GAT CCT CTA CAA GC-3'), 
human TGF-β1 (forward 5′-GCCCTGGACACCAACTATTG-3′, reverse 5′-
CGTGTCCAGGCTCCAAATG-3′), human TGF-β2, (forward 5′-
AAGCTTACACTGTCCCTGCTGC-3′, reverse 5′-TGTGGAGGTGCCATCAATACCT-
3′), human TGF-β3 (forward 5′-ATG ACC CAC GTC CCC TAT CA-3′, reverse 5′-CAG 
ACA GCC AGT TCG TTG TG-3′), murine HPRT-1 (forward 5'- 
TTGCTGACCTGCTGGATTAC -3', reverse 5'-TTTATGTCCCCCGTTGACTG -3), 
murine TGF-β1 (forward 5′- TGGAGCAACATGTGGAACTC -3′, reverse 5′- 
GTCAGCAGCCGGTTACCA -3′), murine TGF-β2, (forward 5′- 
GCCCACTTTCTACAGACCCT -3′, reverse 5′- CCTTGCTATCGATGTAGCGC -3′ ), 
murine human TGF-β3 (forward 5′-AGCATCCACTGTCCATGTCA-3′, reverse 5′-
TTCTTCCTCTGACTGCCCTG-3′), murine ARF-1 (forward 5'-
TCAGCTTCACCGTGTGGGATGT-3′, reverse 5′-CCTCGTTCACACGCTCTCTGTC). 
For expression analysis of human targets in oligonucleotide-treated xenograft mouse 
models, the following human-specific primers were used: TGF-β1 (forward 5′- 
CAATTCCTGGCGATACCTCAG-3′, reverse-5′-GCACAACTCCGGTGACATCAA-3′), 
TGF-β2 (forward 5′-CAGCACACTCGATATGGACCA-3′, reverse 5′-
CCTCGGGCTCAGGATAGTCT-3′), TGF-β3 (forward 5′-
AACGGTGATGACCCACGTC-3′, reverse 5′-CCGACTCGGTGTTTTCCTGG-3′), 
plasminogen activator inhibitor (PAI)-1 (forward 5′-
CAGAAAGTGAAGATCGAGGTGAAC-3′, reverse 5′-
GGAAGGGTCTGTCCATGATGAA-3′), HPRT1 (forward 5′- 
TGAGGATTTGGAAAGGGTGT-3′, reverse 5′- GAGCACACAGAGGGCTACAA-3′). 
 Immunoblot (antibody information) 
The following antibodies were used: anti-pSMAD2 (3108S), anti-pSMAD1/5 (41D10, 
both Cell Signaling, Boston, MA), anti-β-actin (sc-1616, Santa Cruz Biotechnology, 
Santa Cruz, CA), anti-GAPDH (EB07069, Everest Biotech, Oxfordshire, UK), anti-
TGF-β1 (G1221, Promega, Madison, MI), anti-TGF-β2 (ab36495), anti-TGF-β3 
(ab15537). 
 
 
